Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
University of Michigan Rogel Cancer Center
Hoffmann-La Roche
Bristol-Myers Squibb
Mayo Clinic
Imugene Limited
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
Academic and Community Cancer Research United
Ludwig Institute for Cancer Research
SWOG Cancer Research Network
Sumitomo Pharma America, Inc.
Eisai Inc.
MedImmune LLC
Incyte Corporation
University of Louisville
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Northwestern University
Eli Lilly and Company
Merck Sharp & Dohme LLC
Memorial Sloan Kettering Cancer Center
NYU Langone Health
Massachusetts General Hospital
Massachusetts General Hospital
SCRI Development Innovations, LLC
M.D. Anderson Cancer Center
Merck KGaA, Darmstadt, Germany
AstraZeneca
Case Comprehensive Cancer Center